Loading…
3 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2022 | Percentile | Sector n |
|---|---|---|---|---|
| Pardi Medikals | (unclassified) | 39.8% | 84th pct | 1230 |
| Lotusi | Healthcare Services | 15.2% | 60th pct | 296 |
| Shik Bebe | FMCG | 6.6% | 53rd pct | 579 |
Percentile is within each company's own sector across the whole FY2022 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2022 | Pardi Medikals | Lotusi | Shik Bebe |
|---|---|---|---|
| Margins | |||
| Gross Margin | 68.4% | 87.9% | 43.0% |
| EBITDA Margin | 39.8% | 15.2% | 6.6% |
| EBITDAR | 1,204 | 351 | 287 |
| EBITDAR Margin | 42.1% | 21.3% | 22.0% |
| EBIT Margin | 39.6% | 5.9% | 6.6% |
| Net Profit Margin | 41.9% | 8.2% | 6.5% |
| Operating Expense % of Sales | 28.6% | 72.7% | 36.4% |
| Returns | |||
| Return on Assets (ROA) | 77.1% | 5.2% | 8.6% |
| Return on Equity (ROE) | 84.3% | 9.7% | N/A |
| ROIC [EBIT / Invested Capital] | 84.2% | 4.9% | N/A |
| Leverage & debt balances | |||
| Debt-to-Assets | 0.7% | 23.2% | 0.8% |
| Debt-to-Equity | 0.01x | 0.44x | -0.03x |
| Debt-to-EBITDA | 0.01x | 2.44x | 0.09x |
| Equity-to-Assets | 91.4% | 52.9% | -26.8% |
| Net Debt | -77 | 591 | -5 |
| Cash & Equivalents | 88 | 20 | 13 |
| Total Debt | 11 | 611 | 8 |
| Liquidity & working capital | |||
| Current Ratio | 0.00x | 0.87x | 0.76x |
| Quick Ratio | 0.00x | 0.87x | 0.76x |
| Cash Ratio | 0.66x | 0.03x | 0.01x |
| Total Current Assets | 0 | 544 | 952 |
| Total Current Liabilities | 134 | 626 | 1,257 |
| Inventory | N/A | N/A | N/A |
| Trade Receivables | 1,018 | 17 | 87 |
| Trade Payables | 109 | 116 | 1,257 |
| Net Working Capital | -134 | -83 | -305 |
| Net Working Capital % of Revenue | -4.7% | -5.0% | -23.3% |
| Trade Working Capital | 908 | -99 | -1,170 |
| Trade Working Capital % of Revenue | 31.7% | -6.0% | -89.4% |
| Change in Trade Working Capital | N/A | N/A | N/A |
| Turnover & efficiency | |||
| Inventory Turnover | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A |
| Receivables Turnover | 2.81x | 97.35x | 15.11x |
| Days Sales Outstanding (DSO) | 129.8 | 3.7 | 24.2 |
| Payables Turnover | 8.27x | 1.71x | 0.59x |
| Days Payable Outstanding (DPO) | 44.1 | 213.1 | 614.9 |
| Cash Conversion Cycle | 85.7 days | -209.4 days | -590.8 days |
| Asset Turnover | 1.84x | 0.63x | 1.31x |
| Cash flow & dividends | |||
| Operating Cash Flow | 4 | -13 | -29 |
| Free Cash Flow (OCF − Capex proxy) | 4 | -13 | -29 |
| Cash Conversion (OCF / EBITDA) | 0.3% | -5.4% | -33.7% |
| Dividends Declared | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A |